Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 11Stomach Neoplasms 6Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Gastric Adenocarcinoma 2Cholangiocarcinoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Neoplasms of Digestive Organs 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Stromal Tumors 1Fludzoparib" and Anti-angiogenic 1Colonic Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Advanced Primary Liver Cancer 1Advanced Biliary Tract Carcinoma 1Adebrelimab 1

Interventions

Methotrexate 2zimberelimab 1camrelizumab 1apatinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Drug Therapy 1Dactinomycin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gestational Trophoblastic Disease × apatinib × 1 year × Clear all
NCT05139095 2026-02-05

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Peking Union Medical College Hospital

Phase 2 Recruiting
70 enrolled
Gynecologic

Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡